Ocular Therapeutix, Inc. (OCUL)
10.78
-0.30
(-2.66%)
USD |
NASDAQ |
Aug 24, 16:00
10.78
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix EPS Diluted (Quarterly) : -0.3501 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3501 |
| March 31, 2026 | -0.3954 |
| December 31, 2025 | -0.29 |
| September 30, 2025 | -0.3774 |
| June 30, 2025 | -0.3929 |
| March 31, 2025 | -0.3781 |
| December 31, 2024 | -0.288 |
| September 30, 2024 | -0.2185 |
| June 30, 2024 | -0.264 |
| March 31, 2024 | -0.4912 |
| December 31, 2023 | -0.3461 |
| September 30, 2023 | -0.2533 |
| June 30, 2023 | -0.265 |
| March 31, 2023 | -0.3918 |
| December 31, 2022 | -0.2018 |
| September 30, 2022 | -0.3142 |
| June 30, 2022 | -0.2472 |
| March 31, 2022 | -0.2227 |
| December 31, 2021 | -0.2258 |
| September 30, 2021 | -0.2348 |
| June 30, 2021 | -0.2532 |
| March 31, 2021 | -0.2386 |
| December 31, 2020 | -1.212 |
| September 30, 2020 | -0.1896 |
| June 30, 2020 | -0.6374 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4145 |
| December 31, 2019 | -0.5366 |
| September 30, 2019 | -0.4458 |
| June 30, 2019 | -0.5699 |
| March 31, 2019 | -0.4526 |
| December 31, 2018 | -0.4234 |
| September 30, 2018 | -0.3847 |
| June 30, 2018 | -0.37 |
| March 31, 2018 | -0.40 |
| December 31, 2017 | -0.44 |
| September 30, 2017 | -0.54 |
| June 30, 2017 | -0.64 |
| March 31, 2017 | -0.58 |
| December 31, 2016 | -0.52 |
| September 30, 2016 | -0.39 |
| June 30, 2016 | -0.46 |
| March 31, 2016 | -0.44 |
| December 31, 2015 | -0.43 |
| September 30, 2015 | -0.47 |
| June 30, 2015 | -0.45 |
| March 31, 2015 | -0.35 |
| December 31, 2014 | -0.37 |
| September 30, 2014 | -0.48 |
| June 30, 2014 | -2.10 |
| March 31, 2014 | -0.329 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| EyePoint, Inc. | -1.092 |
| LENZ Therapeutics, Inc. | -1.017 |
| Merck & Co., Inc. | -0.5405 |
| Theravance Biopharma, Inc. | -0.1142 |
| ANI Pharmaceuticals, Inc. | 1.052 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -78.76M |
| Revenue (Quarterly) | 13.48M |
| Total Expenses (Quarterly) | 92.24M |
| Enterprise Value | 1.914B |
| Gross Profit Margin (Quarterly) | 85.08% |
| Profit Margin (Quarterly) | -584.5% |
| Earnings Yield | -13.10% |
| Normalized Earnings Yield | -13.13 |